Will CBD Start Being Produced to Factory Precision Like Other Medicines?

February 3, 2020 16:00:12

Cannabidiol (CBD), is undoubtedly one of the break-out drugs of the decade. Even though a lot of the medical claims haven’t been proven yet, and it is extracted from a plant fraught with controversy, CBD is still going strong. More people are turning towards it to help manage their ailments, companies are investing tons of cash in the sector and regulatory authorities are scrambling to regulate the runaway sector.

The hemp extract is part of a group of compounds produced by the cannabis plant called cannabinoids, and these chemicals, with CBD in the lead, have shown great promise as natural medicines. CBD is said to be effective against a plethora of conditions ranging from anxiety and chronic pain to high blood pressure and insomnia.

However, cannabidiol is a natural compound, and as all things in nature, has a limited lifespan. In CBD’s case, loss of potency is equivalent to death, and after a certain period, it becomes useless. But a lot of other medicines don’t go bad. In fact, you could buy a $4.99 bottle of say, Advil, and six, seven months later it will be as potent as the day you bought it. Why can’t we do that with the plethora of CBD products on the market?

Well, Advil, like many other drugs, is a factory medicine, prepared in sterile labs to incredible precision and with longer shelf lives. And that wouldn’t be so bad for the CBD sector. For an industry that’s filled with lots of substandard products, and always plagued with complaints of mislabeled and contaminated products, a little factory precision wouldn’t hurt.

The U.S. Food and Drug Administration, although a little late to the CBD party, has been taking steps to ensure cannabinoids, especially CBD, are prepared like other pharmaceuticals, precisely and consistently. In June 2018, the agency approved Epidiolex, a CBD-based drug made by British pharmaceutical company GW Pharma, to treat seizures caused by two rare pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.

The agency also sent numerous warning letters to CBD companies, warning them against making unproven medical claims.

Cannabidiol companies are catching on, and they’re spending more resources to stay on the FDA’s good side and to give their products a more factory-produced feel by working on shelf stability, standard dosing and a supply chain that will allow the CBD products to reach a much wider market.

One issue CBD producers will definitely run into will be the uniqueness of each hemp plant. Since no two plants are identical, their CBD output will also vary, and this could make it difficult to produce standardized cannabidiol products that are similar across the board. Maybe cannabidiol isn’t destined to be a factory produced medicine, maybe it is. Only time will tell.

Experts believe that sector players like HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) are doing everything they can to standardize the industry so that consumers can have their needs met in a more reliable way.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.